Tulane GI and Liver Research

Salix RNLC3131: A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of Rifaximin soluble solid dispersion (SSD) tablets for the delay of encephalopathy decompensation in cirrhosis (PI: Dr. Fredric Regenstein) NCT05071716 

Nearly half of people living with cirrhosis get hepatic encephalopathy (HE). HE is a complication of cirrhosis that can cause symptoms like:

• Confusion and personality changes
• Loss of small hand movements
• Tremors in hands and arms
• Sleep problems

The RNLC3131 Study is looking to see if a study medicine, rifaximin, can safely delay or prevent HE in adults with advanced liver cirrhosis. You may be eligible to participate if you are between the ages of 18 and 85 and have been diagnosed with liver cirrhosis..

Escient EP 547-201: A clinical research study to investigate EP547 for patients with itch associated with liver disease (PI: Dr. Fredric Regenstein)  NCT05525520

The EP 547-201 study is testing an investigational drug (EP547) to see if it can help reduce itching, also known as pruritus, in adults with cholestatic liver disease.

You may be able to participate in the PACIFIC study if all the following criteria are met:

• You are 18 years of age or older.
• You have daily or near-daily moderate to severe itching (pruritus) due to PBC or PSC.
• If currently taking medications to treat liver disease or pruritus, you must be on a stable dose for certain period of time prior to study entry and willing to maintain a stable regimen throughout the study.